^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ES2B-C001

    i
    Other names: ES2B-C001, AV001, HER2-cVLP, HER2 casid virus like particle
    Associations

    News

    Trials
    Company:
    AdaptVac, ExpreS2ion
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Preclinical activity of ES2B-C001, a human candidate HER-2 virus-like particle (VLP) vaccine, against mammary carcinoma onset and metastasis (AACR 2023)
    Antibodies inhibited the 3D growth of human HER-2+++ and HER-2++ breast cancer cells, of trastuzumab resistant cells and of gastric carcinoma cells. Vaccination increased interferon-gamma secreting cells in the spleen, as evaluated by ELISPot (21±3 spots/2x105 cells). The results warrant further development of ES2B-C001 for the therapy of HER-2 positive human breast cancer and of other tumors expressing HER-2.
    Preclinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma)
    |
    HER-2 positive • HER-2 expression
    |
    Herceptin (trastuzumab) • ES2B-C001
    2years
    Prevention and Therapy of Metastatic HER-2 Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine. (PubMed, Biomedicines)
    Antibodies inhibited the 3D growth of human HER-2 trastuzumab-sensitive and -resistant breast cancer cells. ES2B-C001 is a promising candidate vaccine for the therapy of tumors expressing HER-2. Preclinical results warrant further development towards human clinical studies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • IFNG (Interferon, gamma)
    |
    HER-2 expression
    |
    Herceptin (trastuzumab) • ES2B-C001